Indapta Therapeutics applies TIMING to elucidate the mechanisms of enhanced ADCC featuring CellChorus®
HOUSTON, Texas — November 20, 2024. Indapta Therapeutics (Houston, TX & Seattle, WA) presented data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting featuring data from the CellChorus® Time-lapse Imaging Microscopy In Nanowell Grids™ (TIMING™) platform demonstrating that the enhanced antibody-dependent cellular cytotoxicity (ADCC) of the company’s allogeneic g-NK cells is driven in part by faster cell migration and a higher frequency of synapse formation with target cells compared to conventional NK cells.
